Headquarters: Ness Ziona, Israel
Investor Relations: Eric Ribner / eric@lifesciadvisors.com

Description
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions.
Industry
Life Sciences
Year Founded
Website
Ownership
Public
Exchange / Symbol
NASDAQ: ENLV